Buy Flubrotizolam Pellets
€ 16,95 – € 299,95Price range: € 16,95 through € 299,95
Flubrotizolam Pellets are described as a laboratory research preparation associated with flubrotizolam, a synthetic brominated and fluorinated thienotriazolodiazepine structurally related to brotizolam.
Raw Lab Chems identifies this material exclusively within the context of controlled chemical identification, chromatographic characterization, forensic analytical investigation, and comparative research involving benzodiazepine-related compounds.
The supplied information describes a compressed pellet presentation but does not specify a confirmed labeled ingredient amount for this particular listing.
Claims concerning ingredient purity, independent analytical verification, standardized pellet content, batch consistency, and controlled storage require supporting product-specific documentation.
The material is not established as a certified reference standard or validated quantitative calibrator.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Flubrotizolam Pellets – Thienotriazolodiazepine Research Material
Product Overview
Flubrotizolam Pellets are described in the supplied information as a laboratory research preparation associated with flubrotizolam, a synthetic compound belonging to the thienotriazolodiazepine family.
The compound is structurally related to brotizolam and is distinguished by its brominated and fluorinated molecular framework.
These structural characteristics provide a basis for analytical investigations involving chemical identification, chromatographic differentiation, and spectroscopic characterization.
Raw Lab Chems presents this material exclusively within a Research Use Only framework.
The supplied source describes compressed pellets intended for controlled laboratory examination.
However, the stated presentation does not independently establish the actual chemical identity, purity, finished-unit composition, or content uniformity.
The source also refers to independent analytical verification, batch consistency, and controlled storage.
These statements originated in material associated with another supplier and cannot be attributed to Raw Lab Chems without independent documentation.
No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description.
Chemical Identity & Classification
Flubrotizolam is described in the supplied source as a thienotriazolodiazepine derivative.
The compound contains a fused thiophene-associated diazepine framework and an additional triazole ring.
Its molecular structure distinguishes it from classical benzodiazepines through the replacement of a benzene ring with a thiophene-containing system.
The supplied source provides the following chemical-reference information:
- Common name: Flubrotizolam
- Reported systematic name: 2-Bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
- Chemical classification: Brominated and fluorinated thienotriazolodiazepine derivative
- Reported CAS Registry Number: 57801-95-3
- Reported molecular formula: C15H10BrFN4S
- Reported molecular weight: 377.23 g/mol
These identifiers are reproduced from the supplied information and do not independently verify the composition of the actual product.
The reported molecular formula and molecular weight are approximately consistent with one another.
However, consistency between a formula and calculated mass does not establish that the actual pellet ingredient has been independently identified.
The source does not provide a verified salt-form designation or complete formulation specification.
This distinction matters because the composition of a finished pellet may differ from the molecular formula of the named chemical.
Researchers seeking public chemical-reference information may consult PubChem and confirm that any selected database entry corresponds to the intended compound and chemical form.
Chemical & Physical Characteristics
The supplied product is described as compressed pellets containing flubrotizolam.
No product-specific inspection report, pellet-dimension specification, excipient list, or formulation-characterization record was provided.
The stated physical presentation therefore remains a source-provided description.
The flubrotizolam molecular framework contains a fused thiophene-triazolodiazepine ring system and substituents that distinguish it from related benzodiazepine derivatives.
These structural features provide a basis for analytical differentiation through chromatographic and spectroscopic techniques.
However, structural similarity does not establish identical physical properties, stability, impurity profiles, or analytical behavior.
The source identifies hydroxylated metabolites as topics of forensic and chemical research.
No product-specific hydrolysis-rate measurements, degradation data, or experimentally verified physicochemical profile accompanied this description.
The source also does not provide a verified melting point, quantitative solubility profile, density, particle-size distribution, or hygroscopicity measurement.
The finished pellet preparation may contain additional formulation ingredients that were not identified in the source.
No verified binder, filler, coating, or excipient information accompanied the supplied material.
The source recommends dry, dark storage under controlled temperature conditions and suggests frozen storage for longer-term preservation.
No validated stability study, degradation profile, or experimentally established shelf-life specification accompanied this recommendation.
Purity & Analytical Verification
The supplied description claims purity of at least 98%, with independent quality-control testing cited as verification.
It also refers to analytical purity profiles and Certificates of Analysis.
However, no actual Raw Lab Chems batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, or independent laboratory report was provided.
Accordingly, the stated purity threshold is not independently confirmed for the material described here.
The source identifies LC-MS/MS and LC-HRMS/MS as analytical techniques associated with flubrotizolam investigation.
Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity.
However, naming an analytical technique does not establish that it was performed on the actual product.
An important distinction exists between the purity of the chemical ingredient and the composition of the finished pellet.
Even if ingredient purity were independently established, that finding would not by itself verify the labeled component amount, total formulation, or consistency between individual units.
The source also references hydroxylated metabolites as potential analytical markers.
These references provide scientific context rather than evidence of the product’s verified performance in a particular laboratory method.
No certified reference-material status, validated finished-unit content, or independently established purity specification is asserted.
Quality Control & Batch Integrity
The supplied source claims that individual batches undergo independent testing and are supported by Certificates of Analysis.
It also describes standardized pellet content, controlled storage, and double-sealed packaging.
No actual certificate, independent testing record, manufacturing audit, laboratory accreditation document, or batch-specific quality-control report accompanied these statements.
They therefore remain unverified claims. Flubrotizolam Pellets
Furthermore, the source refers to a supplier other than Raw Lab Chems.
Its quality-control representations should not be transferred to a Raw Lab Chems product listing without supporting documentation from the relevant supplier.
For reproducible laboratory investigation, useful records may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings.
For pellet preparations, the identity and purity of the named ingredient should be distinguished from the composition and consistency of the finished units.
The supplied information does not establish independently verified content uniformity, excipient composition, or quantitative accuracy of any labeled amount.
Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material.
The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty.
Safety, Handling & Laboratory Precautions
Flubrotizolam is a benzodiazepine-related compound requiring appropriate institutional risk assessment and controlled laboratory handling. Flubrotizolam Pellets
The source associates the compound with serious central nervous system depressant hazards, including profound impairment and potentially life-threatening toxicity following exposure.
Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.
Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal.
The compound’s structural relationship to brotizolam does not establish safety for human or veterinary exposure.
The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.
Because the actual purity and pellet composition have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.
The pellet presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use. Flubrotizolam Pellets
Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.
Packaging, Labeling & Storage
The supplied source describes double-sealed packaging, temperature-controlled logistics, and tracking during transportation.
No Raw Lab Chems packaging-validation study, verified container specification, shipment-condition record, or carrier documentation accompanied these claims.
The source recommends dry, dark storage under controlled temperature conditions and suggests approximately −20°C for longer-term preservation.
It also claims extended stability under frozen storage.
No validated stability data was provided to establish that this temperature is necessary or sufficient for a particular shelf life.
Claims concerning frozen storage, stability duration, and controlled transport therefore remain unverified.
Laboratory inventory records should preserve the compound name, any available batch identifier, receipt details, and relevant storage observations.
Any labeled pellet content should be recorded as a source-provided specification unless independently confirmed. Flubrotizolam Pellets
Where chemical form or formulation ingredients remain uncertain, the inventory record should preserve those uncertainties rather than assign unverified details.
Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.
Intended Research Use & Market Positioning
The supplied scientific context places flubrotizolam within analytical research involving thienotriazolodiazepine derivatives, chemical identification, structural comparison, and forensic toxicology. Flubrotizolam Pellets
Its brominated and fluorinated molecular framework provides a basis for differentiating it from other benzodiazepine-related compounds in appropriately validated analytical investigations.
The source references chromatographic identification, mass-spectrometric characterization, and investigation of hydroxylated flubrotizolam-related analytical markers.
These references describe laboratory research contexts and do not establish any human-use application.
For comparative chemical-catalog research, Raw Lab Chems also lists Fluclotizolam Pellets and Fluetizolam Pellets.
These listings identify other named research materials but do not establish equivalent chemical identity, purity, formulation, or analytical characteristics.
The supplied catalog also includes Flunitrazolam Blotters, a different benzodiazepine-related compound presented in another format.
These references provide chemical-catalog context rather than evidence of certified reference-material status or interchangeability.
Ordering, Availability & Fulfillment
The supplied source includes claims concerning available pack sizes, European shipping coverage, same-day dispatch, delivery time frames, carrier services, and payment options.
However, those statements reference another supplier and are not verified Raw Lab Chems fulfillment specifications.
No current Raw Lab Chems inventory record, shipping schedule, destination-specific authorization, or carrier documentation was supplied.
Consequently, no particular availability, delivery period, shipping cost, customs-clearance arrangement, or transportation-compliance guarantee is asserted. Flubrotizolam Pellets
Flubrotizolam may be subject to strict controlled-substance legislation.
Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved.
Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions.
Research-only labeling does not establish an exemption from controlled-substance regulations.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Flubrotizolam is a thienotriazolodiazepine whose acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance or other chemical regulations. Flubrotizolam Pellets
The supplied source identifies regulatory restrictions in the United Kingdom and France, but the exact current legal classification was not independently verified for this listing.
Researchers and institutions remain responsible for determining the applicable legal requirements and obtaining any necessary authorizations.
No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.
| Quantity |
10 pellets ,20 pellets ,50 pellets ,100 pellets ,250 pellets |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.